Skip to main content
Erschienen in: Hepatology International 2/2018

12.04.2018 | Original Article

Spectrum of histopathological changes in patients with non-cirrhotic portal fibrosis

verfasst von: Abhijit Chougule, Archana Rastogi, Rakhi Maiwall, Chhagan Bihari, Vikrant Sood, Shiv Kumar Sarin

Erschienen in: Hepatology International | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Non-cirrhotic portal fibrosis (NCPF) is a clinical disorder characterized by features of portal hypertension in the absence of significant fibrosis. It is one of the commonest causes of portal hypertension in India. This study aimed to analyze histomorphological spectrum of NCPF in detail.

Methods and Results

There were 67 specimens from 66 patients which included 43 (65.2%) male and 23 (34.8%) female patients with a mean age of 31 years (range: 7–61 years). The liver function tests showed only a mild derangement. The average length of biopsy was 1.4 cm (median: 1.2 cm, range: 0.8–3.4 cm) and the mean number of portal tracts per biopsy was 11.1 (median: 10, range: 5–30). Most cases showed a combination of histological features; the mean number of histological features per biopsy was 7.4 (median: 7, range: 3–12). Obliterative portal venopathy was seen in 47.8% cases. Portal angiomatosis (61.2%), paraportal shunt vessels (61.2%), portal vein dilatation (74.6%), hypoplastic portal tracts (56.7%), megasinusoids (64.1%), and abnormally dilated central veins (64.1%) were other prevalent features. Portal/periportal fibrosis and perisinusoidal fibrosis were seen in 77.6% and 61.2% cases; none showed bridging fibrosis or cirrhosis. The median hepatic venous pressure gradient (HVPG) and liver stiffness (LS) values were 8 mm of Hg (range: 5–20 mm of Hg) and 9.2 kPa (range: 4.4–26.3 kPa). There was no correlation of HVPG or LS with either portal/periportal fibrosis or perisinusoidal fibrosis.

Conclusion

Due to relatively non-specific and non-pathognomonic nature, a combination of different histological features in the absence of significant fibrosis and appropriate clinico-radiological background is needed for diagnosing NCPF.
Literatur
1.
Zurück zum Zitat Khanna R, Sarin SK. Non-cirrhotic portal hypertension—diagnosis and management. J Hepatol 2014;60:421–441.CrossRefPubMed Khanna R, Sarin SK. Non-cirrhotic portal hypertension—diagnosis and management. J Hepatol 2014;60:421–441.CrossRefPubMed
2.
Zurück zum Zitat Sarin SK, Kumar A, Chawla YK, et al. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int 2007;1:398–413.CrossRefPubMedPubMedCentral Sarin SK, Kumar A, Chawla YK, et al. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int 2007;1:398–413.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Goel A, Elias JE, Eapen CE, Ramakrishna B, Elias E. Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH)-newer insights into pathogenesis and emerging newer treatment options. J Clin Exp Hepatol 2014;4:247–256.CrossRefPubMedPubMedCentral Goel A, Elias JE, Eapen CE, Ramakrishna B, Elias E. Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH)-newer insights into pathogenesis and emerging newer treatment options. J Clin Exp Hepatol 2014;4:247–256.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011;54:1071–1081.CrossRefPubMed Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011;54:1071–1081.CrossRefPubMed
5.
Zurück zum Zitat de Franchis R, Baveno VI. Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743–752.CrossRefPubMed de Franchis R, Baveno VI. Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743–752.CrossRefPubMed
6.
Zurück zum Zitat Nayak NC, Jain D, Saigal S, Soin AS. Non-cirrhotic portal fibrosis: one disease with many names? An analysis from morphological study of native explant livers with end stage chronic liver disease. J Clin Pathol 2011;64:592–598.CrossRefPubMed Nayak NC, Jain D, Saigal S, Soin AS. Non-cirrhotic portal fibrosis: one disease with many names? An analysis from morphological study of native explant livers with end stage chronic liver disease. J Clin Pathol 2011;64:592–598.CrossRefPubMed
7.
Zurück zum Zitat Lee H, Rehman AU, Fiel MI. Idiopathic noncirrhotic portal hypertension: an appraisal. J Pathol Transl Med 2016;50:17–25.CrossRefPubMed Lee H, Rehman AU, Fiel MI. Idiopathic noncirrhotic portal hypertension: an appraisal. J Pathol Transl Med 2016;50:17–25.CrossRefPubMed
8.
Zurück zum Zitat Verheij J, Schouten JNL, Komuta M, et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology 2013;62:1083–1091.CrossRefPubMed Verheij J, Schouten JNL, Komuta M, et al. Histological features in western patients with idiopathic non-cirrhotic portal hypertension. Histopathology 2013;62:1083–1091.CrossRefPubMed
9.
Zurück zum Zitat Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996;28:195–204.CrossRefPubMed Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996;28:195–204.CrossRefPubMed
10.
Zurück zum Zitat Seijo S, Reverter E, Miquel R, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis 2012;44:855–860.CrossRefPubMed Seijo S, Reverter E, Miquel R, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis 2012;44:855–860.CrossRefPubMed
11.
Zurück zum Zitat Kumar A, Sharma P, Sarin SK. Hepatic venous pressure gradient measurement: time to learn. Indian J Gastroenterol 2008;27:74–80.PubMed Kumar A, Sharma P, Sarin SK. Hepatic venous pressure gradient measurement: time to learn. Indian J Gastroenterol 2008;27:74–80.PubMed
12.
Zurück zum Zitat Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002;51:275–280.CrossRefPubMedPubMedCentral Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002;51:275–280.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Madhu K, Avinash B, Ramakrishna B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol 2009;28:83–87.CrossRefPubMed Madhu K, Avinash B, Ramakrishna B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol 2009;28:83–87.CrossRefPubMed
14.
Zurück zum Zitat Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009;104:1707–1714.CrossRefPubMed Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009;104:1707–1714.CrossRefPubMed
15.
Zurück zum Zitat Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol 2011;54:455–461.CrossRefPubMed Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol 2011;54:455–461.CrossRefPubMed
16.
Zurück zum Zitat Sood V, Lal BB, Khanna R, Rawat D, Sharma CB, Alam S. Non-cirrhotic portal fibrosis in pediatric population. J Pediatr Gastroenterol Nutr 2017;64:748–753.CrossRefPubMed Sood V, Lal BB, Khanna R, Rawat D, Sharma CB, Alam S. Non-cirrhotic portal fibrosis in pediatric population. J Pediatr Gastroenterol Nutr 2017;64:748–753.CrossRefPubMed
17.
Zurück zum Zitat Scourfield A, Waters L, Holmes P, et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011;22:324–348.CrossRefPubMed Scourfield A, Waters L, Holmes P, et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011;22:324–348.CrossRefPubMed
18.
19.
Zurück zum Zitat Riggio O, Gioia S, Pentassuglio I, Nicoletti V, Valente M, d’Amati G. Idiopathic noncirrhotic portal hypertension: current perspectives. Hepat Med 2016;8:81–88.CrossRefPubMedPubMedCentral Riggio O, Gioia S, Pentassuglio I, Nicoletti V, Valente M, d’Amati G. Idiopathic noncirrhotic portal hypertension: current perspectives. Hepat Med 2016;8:81–88.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002;17:6–16.CrossRefPubMed Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002;17:6–16.CrossRefPubMed
21.
Zurück zum Zitat Maiwall R, Goel A, Pulimood AB, et al. Investigation into celiac disease in Indian patients with portal hypertension. Indian J Gastroenterol 2014;33:517–523.CrossRefPubMed Maiwall R, Goel A, Pulimood AB, et al. Investigation into celiac disease in Indian patients with portal hypertension. Indian J Gastroenterol 2014;33:517–523.CrossRefPubMed
22.
Zurück zum Zitat Köksal AS, Köklü S, Ibiş M, et al. Clinical features, serum interleukin-6, and interferon-gamma levels of 34 Turkish patients with hepatoportal sclerosis. Dig Dis Sci 2007;52:3493.CrossRefPubMed Köksal AS, Köklü S, Ibiş M, et al. Clinical features, serum interleukin-6, and interferon-gamma levels of 34 Turkish patients with hepatoportal sclerosis. Dig Dis Sci 2007;52:3493.CrossRefPubMed
23.
Zurück zum Zitat Guido M, Sarcognato S, Sonzogni A, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int 2016;36:454–460.CrossRefPubMed Guido M, Sarcognato S, Sonzogni A, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int 2016;36:454–460.CrossRefPubMed
24.
Zurück zum Zitat Zuo C, Chumbalkar V, Ells PF, Bonville DJ, Lee H. Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies. Hepatol Int 2017;11:452–460.CrossRefPubMed Zuo C, Chumbalkar V, Ells PF, Bonville DJ, Lee H. Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies. Hepatol Int 2017;11:452–460.CrossRefPubMed
25.
Zurück zum Zitat Laharie D, Vergniol J, Bioulac-Sage P, et al. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010;22:487–493.CrossRefPubMed Laharie D, Vergniol J, Bioulac-Sage P, et al. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010;22:487–493.CrossRefPubMed
Metadaten
Titel
Spectrum of histopathological changes in patients with non-cirrhotic portal fibrosis
verfasst von
Abhijit Chougule
Archana Rastogi
Rakhi Maiwall
Chhagan Bihari
Vikrant Sood
Shiv Kumar Sarin
Publikationsdatum
12.04.2018
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 2/2018
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-018-9857-y

Weitere Artikel der Ausgabe 2/2018

Hepatology International 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.